CDSCO Bans 16 Fixed Dose Combinations: What Pharma Companies Need to Know
Effective June 11, 2026, the Central Drugs Standard Control Organisation (CDSCO) has banned the manufacture, sale, and distribution of 16 specific Fixed Dose Combination (FDC) drugs across India. This move follows a series of government notifications (S.O. 3068(E) to S.O. 3083(E)), and it’s a big shift for pharma companies, distributors, and healthcare professionals.
So, why the sudden clampdown? After a close look at the safety, effectiveness, and therapeutic need for these combinations, experts decided they do more harm than good. Companies need to check their current products and act fast to stay compliant.
What Exactly Are Fixed Dose Combinations?
FDCs are medicines that mix two or more active ingredients in a single pill or syrup. When used with good scientific backing, these combinations can help patients stick to their prescriptions and even improve outcomes. But when they’re put together irrationally—without enough scientific support—they can bring unnecessary side effects, promote drug resistance, or simply not work as intended.
The List: Which FDCs Are Now Prohibited?
Here are the combinations you need to halt right away—no delays:
1. Acetyl Salicylic Acid + Ethoheptazine
2. Cefixime + Dicloxacillin
3. Azithromycin + Cefixime
4. Ofloxacin + Cefixime
5. Levocetirizine + Ambroxol + Phenylephrine
6. Paracetamol + Cetirizine + Phenylephrine + Dextromethorphan
7. Nimesulide + Cetirizine
8. Aceclofenac + Paracetamol + Rabeprazole
9. Diclofenac + Paracetamol + Chlorzoxazone + Serratiopeptidase
10. Mefenamic Acid + Dicyclomine + Paracetamol
11. Amoxycillin + Dicloxacillin
12. Cefixime + Ofloxacin + Lactobacillus
13. Cefixime + Azithromycin + Lactobacillus
14. Ambroxol + Guaiphenesin + Terbutaline + Bromhexine
15. Paracetamol + Tramadol + Caffeine
16. Any other combination specified in S.O. 3083(E).
Why CDSCO Pulled the Plug on These FDCs
The government routinely reviews FDCs to make sure they’re safe, effective, justified, and supported by proper clinical data. If any combination doesn’t pass the test—or shows risk to public health—it doesn’t stay on the market. This time, the authorities acted after finding these combos just didn’t have the evidence or therapeutic need to justify their risks.
What Does This Mean for Pharma Companies?
You can’t ignore this one. Take these steps now:
– Audit your products for the listed FDCs.
– Stop making, selling, and distributing the banned combinations at once.
– Pull these products from your supply chain.
– Inform all your partners—distributors, hospitals, retailers—so they don’t get caught off guard.
– Update all your regulatory and quality documents.
– Make sure any new products you develop clear the latest CDSCO requirements.
Skipping these steps leaves you open to heavy regulatory action, including potential penalties under the law.
Wider Impact on the Industry
This prohibition isn’t just about 16 formulas. It signals CDSCO’s push for safer, more evidence-based medicines across India. Companies working on new FDCs can expect tighter reviews and should gather solid data before launching anything new.
Make sure your development pipeline checks all the boxes: scientific rationale, clinical proof, safety data, and proper regulatory approvals.
How ACPL Helps You Stay Compliant
At Accredited Consultants Pvt. Ltd. (ACPL), we specialize in helping pharma companies keep up with evolving regulations. If you’re not sure where to start, or you need hands-on help, our team can guide you through:
– Meeting CDSCO compliance standards
– Navigating drug approval for new products
– Getting FDC products through regulatory review
– Preparing manufacturing and import licenses
– Handling all the documentation and assessments you need to stay in business
We’re based in Noida, but our support covers the needs of clients across India. Our experienced consultants make sure you don’t miss a step or a new requirement.
Wrapping Up
This regulatory update is a wake-up call—don’t sit back and hope things will blow over. Review your product line, talk to your stakeholders, and get compliant. Staying on top of these changes makes sure your business continues smoothly and you avoid unnecessary hassles.
Have questions about CDSCO compliance or need help with FDC approvals? Reach out to ACPL for expert support.
Contact ACPL
Accredited Consultants Pvt. Ltd. (ACPL)
Noida, Uttar Pradesh, India
info@acplgroupindia.co.in
+91-9310336522
If you need clarity on FDC regulations, product bans, or anything in between—call us. We’re here to help.